Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Countries citing papers authored by Dana P. Goldman
Since
Specialization
Citations
This map shows the geographic impact of Dana P. Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana P. Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana P. Goldman more than expected).
This network shows the impact of papers produced by Dana P. Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana P. Goldman. The network helps show where Dana P. Goldman may publish in the future.
Co-authorship network of co-authors of Dana P. Goldman
This figure shows the co-authorship network connecting the top 25 collaborators of Dana P. Goldman.
A scholar is included among the top collaborators of Dana P. Goldman based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Dana P. Goldman. Dana P. Goldman is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Berndt, Ernst R., Dana P. Goldman, & John W. Rowe. (2018). Introduction to "Economic Dimensions of Personalized and Precision Medicine". NBER Chapters. 1–7.1 indexed citations
9.
Goldman, Dana P., Étienne Gaudette, & Wei‐Han Cheng. (2016). Competing Risks. American Journal of Preventive Medicine. 50(5). S45–S50.6 indexed citations
10.
Sun, Eric, Anupam B. Jena, Darius Lakdawalla, et al.. (2015). An economic evaluation of the war on cancer. RePEc: Research Papers in Economics.1 indexed citations
Snider, Julia Thornton, et al.. (2012). The Disability Burden of COPD. COPD Journal of Chronic Obstructive Pulmonary Disease. 9(5). 513–521.48 indexed citations
McGlynn, Elizabeth A., Paul G Shekelle, Susan Chen, et al.. (2008). Identifying, Categorizing, and Evaluating Health Care Efficiency Measures. 49(5). 352–9.37 indexed citations
Goldman, Dana P., Geoffrey Joyce, & Pinar Karaca‐Mandic. (2006). Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.. PubMed. 12(1). 21–8.121 indexed citations
18.
Lakdawalla, Darius, Dana P. Goldman, & Neeraj Sood. (2006). HIV Treatment Breakthroughs and Risky Sexual Behavior. The Quarterly Journal of Economics.3 indexed citations
19.
Bhattacharya, Jay, Dana P. Goldman, & Neeraj Sood. (2004). Price Regulation in Secondary Insurance Markets. SSRN Electronic Journal.2 indexed citations
20.
Hamilton, Barton H., Vivian Ho, & Dana P. Goldman. (2000). Queuing for Surgery. 2. 89–91.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.